[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"usher-syndrome-type-1b\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:usher-syndrome-type-1b":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100561563","phase-1-study-of-subretinally-injected-aavb-081-in-patients-with-usher-syndrome-type-ib-ush1b-retinitis-pigmentosa-100561563",false,"NCT06591793","Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa","A Phase 1\u002F2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Subjects With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa","Inclusion Criteria:\n\n* Molecular diagnosis of USB1B due to MYO7A mutation\n* Willingness to adhere to protocol per informed consent\n\nExclusion Criteria:\n\n* Unwillingness to meet the requirements of the study\n* Participation in a clinical study with an Investigation Product in the past 6 months\n* Previous participation in another Gene Therapy trial\n* Any condition that would preclude subretinal surgery\n* Complicating ocular and\u002For systemic diseases","ALL","18 Years","50 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.",[28],"Usher Syndrome, Type 1B",[30,31,32,33],"Usher Syndrome","MYO7A","USH1B","Retinitis Pigmentosa","RECRUITING","2025-05-01",{"date":37,"type":38},"2025-05-02","ACTUAL",{"date":40,"type":38},"2024-07-02",{"date":42,"type":21},"2029-07",{"name":44,"class":45},"AAVantgarde Bio Srl","INDUSTRY",3]